EA201890623A1 - Рациональная комбинированная терапия для лечения рака - Google Patents

Рациональная комбинированная терапия для лечения рака

Info

Publication number
EA201890623A1
EA201890623A1 EA201890623A EA201890623A EA201890623A1 EA 201890623 A1 EA201890623 A1 EA 201890623A1 EA 201890623 A EA201890623 A EA 201890623A EA 201890623 A EA201890623 A EA 201890623A EA 201890623 A1 EA201890623 A1 EA 201890623A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agents
cancer treatment
combined therapy
rational
rational combined
Prior art date
Application number
EA201890623A
Other languages
English (en)
Inventor
Габриэла Чиосис
Тони Тальдоне
Лиза Шреста
Джон Корен
Эрика М. Гомес-Дагама
Анна Родина
Original Assignee
Мемориал Слоун Кеттеринг Кэнсер Сентр
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мемориал Слоун Кеттеринг Кэнсер Сентр filed Critical Мемориал Слоун Кеттеринг Кэнсер Сентр
Publication of EA201890623A1 publication Critical patent/EA201890623A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

В настоящем изобретении представлены способы применения ингибиторов шаперонных белков, таких как ингибиторы HSP90, в комбинации со средствами, которые увеличивают протеотоксический стресс в опухолевых клетках, или средствами, которые индуцируют биохимическую перестройку шабером. Протеотоксические средства вводят до введения шаперонных белков для достижения синергической активности.
EA201890623A 2015-10-05 2016-10-05 Рациональная комбинированная терапия для лечения рака EA201890623A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562237470P 2015-10-05 2015-10-05
PCT/US2016/055594 WO2017062520A1 (en) 2015-10-05 2016-10-05 Rational combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
EA201890623A1 true EA201890623A1 (ru) 2018-09-28

Family

ID=57145064

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890623A EA201890623A1 (ru) 2015-10-05 2016-10-05 Рациональная комбинированная терапия для лечения рака

Country Status (14)

Country Link
US (1) US20180280397A1 (ru)
EP (1) EP3359196B1 (ru)
JP (1) JP7132848B2 (ru)
KR (1) KR20180058824A (ru)
CN (1) CN108472376A (ru)
AU (1) AU2016336351A1 (ru)
BR (1) BR112018006572A2 (ru)
CA (1) CA3000851A1 (ru)
EA (1) EA201890623A1 (ru)
IL (1) IL258494A (ru)
MA (1) MA47474A (ru)
MX (1) MX2018004112A (ru)
TW (1) TW201722422A (ru)
WO (1) WO2017062520A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014386214B2 (en) 2013-12-23 2020-05-21 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
CN110090303B (zh) * 2019-05-07 2022-09-16 浙江大学 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途
CN112641949A (zh) * 2021-01-11 2021-04-13 深圳市人民医院(深圳市呼吸疾病研究所) 一种含有pi3k抑制剂的药物组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1473055A (zh) 2000-11-02 2004-02-04 ˹¡-�����ְ�֢�о��� 通过使用hsp90抑制剂提高细胞毒剂效力的方法
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
DK2034839T3 (en) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Res TREATMENT OF NEURODEGENERATIVE DISEASES BY INHIBITION OF HSP90
NZ598262A (en) 2009-08-17 2014-05-30 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
ES2733131T3 (es) 2009-10-07 2019-11-27 Sloan Kettering Inst Cancer Res Derivados de purina útiles como inhibidores de hsp90
AU2012240079B2 (en) 2011-04-05 2017-05-18 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
MX360390B (es) 2011-04-05 2018-10-31 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
EP3208615B1 (en) 2011-07-08 2019-10-09 Sloan Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
BR112016003201A2 (pt) 2013-08-16 2017-11-21 Memorial Sloan Kettering Cancer Center inibidores de grp94 seletivos e usos dos mesmos
CA2948621A1 (en) 2014-05-13 2015-11-19 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same

Also Published As

Publication number Publication date
MX2018004112A (es) 2018-06-20
KR20180058824A (ko) 2018-06-01
EP3359196B1 (en) 2022-03-16
IL258494A (en) 2018-05-31
MA47474A (fr) 2019-12-25
JP2018537519A (ja) 2018-12-20
US20180280397A1 (en) 2018-10-04
AU2016336351A1 (en) 2018-05-10
EP3359196A1 (en) 2018-08-15
CN108472376A (zh) 2018-08-31
JP7132848B2 (ja) 2022-09-07
BR112018006572A2 (pt) 2018-10-09
CA3000851A1 (en) 2017-04-13
TW201722422A (zh) 2017-07-01
WO2017062520A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
PH12018502429A1 (en) Antibody molecules for cancer treatment
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
NI201500002A (es) Agentes de unión de rspo3 y usos de los mismos.
BR112018008503A2 (pt) método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer
UA109278C2 (uk) Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань
PE20180260A1 (es) Metodos y kits para tratar la depresion
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
BR112017010761A2 (pt) tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
BR112017018198A2 (pt) inibição da atividade de olig2
BR112018002530A2 (pt) combinações e usos e tratamentos destas
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CO2019003865A2 (es) Proteína terapéutica